Sector Gamma AS Purchases 335,000 Shares of Pfizer Inc. (NYSE:PFE)

Sector Gamma AS boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 40.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,155,000 shares of the biopharmaceutical company's stock after purchasing an additional 335,000 shares during the period. Pfizer makes up about 10.5% of Sector Gamma AS's portfolio, making the stock its biggest position. Sector Gamma AS's holdings in Pfizer were worth $30,642,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the fourth quarter worth $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several brokerages recently weighed in on PFE. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Stock Down 0.6 %

Shares of NYSE:PFE traded down $0.15 during trading on Monday, hitting $26.13. The company's stock had a trading volume of 37,863,216 shares, compared to its average volume of 36,651,219. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The stock's 50-day moving average price is $26.15 and its two-hundred day moving average price is $27.02. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $148.21 billion, a PE ratio of 18.53, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 earnings per share. The company's revenue was up 24.7% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.